Compound (1R) - 1 - ((2R) - 2 - amino - 4 - (8S) - 8 - (cyclohexylmethyl) - 2 - phenyl - 5.6 - dihidroimidazo 1,2-a 7 (8h) - yl - 3-oxopropyl} dithio) methyl - 2 - (8S) - 8 - (cyclohexylmethyl) - 2 - phenyl - 5.6 - dihidroimidazo 1,2-a 7 (8h) - yl - 2 - oxoetilamina and its Salts, Process for their preparation, and Pharmaceutical composition

摘要

A product containing at least one phosphoric acid cdc25 inhibitor, in combination with at least another anticancer agent for treatment, is simultaneous, independent, or long-term in the treatment of cancer. Another anticancer agent is best selected from the following substances: analogues of DNA base such as 5-fluorohydrazine; one and / or two types of polyphosphate inhibitors, such as camptotecina and its analogues, doxorubicina or amsakina; compounds that interact with body cells such as pacitacxel (Taxol);a. Compounds that act on the cytoskeleton, such as vinblastine; inhibitors of allogeneic protein G; inhibitors of acrylonitrile transfer, especially farnesil transfer ASA; Cyclocarbamate attachment inhibitors (CDKs);Other current targets are (1R) - 1 - [((2R) - 2-amino-3 - [(8s) - 8 - (cicicichiohlmetry) - 2-fenil-5, 6-dihydromidazo [1], 2-A] pyridine-7 (8h) - II] - 3-oxopropil} dimethyl] - 2 - [(8s) - 8 - (cyclohexane) - 2-phenyl-5,6-pyridine-7 [1,2-a] pyridine-7 (8h) - Il] - 2-oxoetilamine, or an acceptable salt for drug use, as an anticancer agent.